Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed/refractory acute myeloid leukemia: an EBMT analysis.
Rodríguez-Arbolí E, Labopin M, Eder M, Brecht A, Blau IW, Huynh A, Forcade E, Tischer J, Bethge W, Bondarenko S, Verbeek M, Bulabois CE, Einsele H, Stölzel F, Savani B, Spyridonidis A, Bazarbachi A, Giebel S, Brissot E, Schmid C, Nagler A, Mohty M. Rodríguez-Arbolí E, et al. Among authors: tischer j. Bone Marrow Transplant. 2022 Jun;57(6):934-941. doi: 10.1038/s41409-022-01611-y. Epub 2022 Apr 7. Bone Marrow Transplant. 2022. PMID: 35393528
In-vivo generation of leukaemia-derived dendritic cells.
Kolb HJ, Rank A, Chen X, Woiciechowsky A, Roskrow M, Schmid C, Tischer J, Ledderose G. Kolb HJ, et al. Among authors: tischer j. Best Pract Res Clin Haematol. 2004 Sep;17(3):439-51. doi: 10.1016/j.beha.2004.06.004. Best Pract Res Clin Haematol. 2004. PMID: 15498715 Review.
DLI: where are we know?
Kolb HJ, Schmid C, Buhmann R, Tischer J, Ledderose G. Kolb HJ, et al. Among authors: tischer j. Hematology. 2005;10 Suppl 1:115-6. doi: 10.1080/10245330512331390122. Hematology. 2005. PMID: 16188651 No abstract available.
Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation.
Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D, Harsdorf SV, Scheid C, Holtick U, Greinix H, Keil F, Schneider B, Sandherr M, Bug G, Tischer J, Ledderose G, Hallek M, Hiddemann W, Kolb HJ. Schmid C, et al. Among authors: tischer j. Blood. 2006 Aug 1;108(3):1092-9. doi: 10.1182/blood-2005-10-4165. Epub 2006 Mar 21. Blood. 2006. PMID: 16551971 Free article. Clinical Trial.
High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission.
Schmid C, Schleuning M, Hentrich M, Markl GE, Gerbitz A, Tischer J, Ledderose G, Oruzio D, Hiddemann W, Kolb HJ. Schmid C, et al. Among authors: tischer j. Bone Marrow Transplant. 2008 Apr;41(8):721-7. doi: 10.1038/sj.bmt.1705965. Epub 2008 Jan 7. Bone Marrow Transplant. 2008. PMID: 18176613
The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
Grabrucker C, Liepert A, Dreyig J, Kremser A, Kroell T, Freudenreich M, Schmid C, Schweiger C, Tischer J, Kolb HJ, Schmetzer H. Grabrucker C, et al. Among authors: tischer j. J Immunother. 2010 Jun;33(5):523-37. doi: 10.1097/CJI.0b013e3181d87ffd. J Immunother. 2010. PMID: 20463595
Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential.
Liepert A, Grabrucker C, Kremser A, Dreyssig J, Ansprenger C, Freudenreich M, Kroell T, Reibke R, Tischer J, Schweiger C, Schmid C, Kolb HJ, Schmetzer H. Liepert A, et al. Among authors: tischer j. Cell Immunol. 2010;265(1):23-30. doi: 10.1016/j.cellimm.2010.06.009. Epub 2010 Jun 20. Cell Immunol. 2010. PMID: 20663492
Early allo-SCT for AML with a complex aberrant karyotype--results from a prospective pilot study.
Schmid C, Schleuning M, Tischer J, Holler E, Haude KH, Braess J, Haferlach C, Baurmann H, Oruzio D, Hahn J, Spiekermann K, Schlimok G, Schwerdtfeger R, Buechner T, Hiddemann W, Kolb HJ. Schmid C, et al. Among authors: tischer j. Bone Marrow Transplant. 2012 Jan;47(1):46-53. doi: 10.1038/bmt.2011.15. Epub 2011 Feb 28. Bone Marrow Transplant. 2012. PMID: 21358688 Clinical Trial.
165 results